Canopy Growth (CGC) revenue breakdown

Healthcare · Drug Manufacturers - Specialty & Generic · Market cap $354M

By segment, Cannabis is the largest at 75% of fiscal 2026 revenue, growing 6% a year over 2 years.

By region, CANADA is the largest at 65% of fiscal 2026 revenue; Germany grew fastest, 19% a year over 7 years.

Revenue by segment

Fiscal years, as Canopy Growth reports them in its 10-K filings; fiscal 2026 total $285M.

Segments20192020202120222023202420252026Share
Cannabis—————$192M$187M$214M 75%
Storz & Bickel——$81M$85M$65M$79M$82M$71M 25%
This Works—————$21M—— —
Other—————$5M—— —
Global Cannabis$192M$295M—————— —
Canada Cannabis——$285M$258M$195M——— —
International Markets Cannabis——$94M$79M$39M——— —
BioSteel——$29M————— —
This Works——$33M$32M$26M——— —
Other$34M$104M$25M$21M$8M——— —

Revenue by region

Fiscal years, as Canopy Growth reports them in its 10-K filings; fiscal 2026 total $285M.

Regions20192020202120222023202420252026Share
CANADA$198M$256M$329M$268M$201M$163M$156M$186M 65%
Germany$18M$94M$116M$91M$49M$52M$60M$62M 22%
United States$10M$25M$65M$65M$36M$41M$36M$28M 10%
Other$6,000$24M$36M$51M$47M$41M$17M$8M 3%
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for CGC.
Open CGC in Investingly

Questions

Where does Canopy Growth make its money?

In fiscal 2026, by segment: Cannabis $214M, Storz & Bickel $71M.

From Canopy Growth's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.